NCT05265988View on ClinicalTrials.gov

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

June 29, 2024

Study Completion Date

June 29, 2024

Conditions
Carcinoma Prostate
Interventions
DRUG

Cabozantinib

Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy

Trial Locations (1)

25123

Alfredo Berruti, Brescia

All Listed Sponsors
lead

Alfredo Berruti

OTHER

NCT05265988 - Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib | Biotech Hunter | Biotech Hunter